Quick Answer
LEXICON PHARMACEUTICALS, INC. reported Operating Income Loss of -$48.91 million for the year ending 2025.
- LEXICON PHARMACEUTICALS, INC. showed an increase of +75.2% in Operating Income Loss from 2024 to 2025.
- This data is from LEXICON PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: -$31.22 million | Q4 2013: -$16.98 million | Q1 2014: -$30.47 million | Q2 2014: -$26.11 million | Q3 2014: -$40.34 million | Q4 2014: -$3.45 million | Q1 2015: -$26.53 million | Q2 2015: -$26.69 million | Q3 2015: -$33.68 million | Q4 2015: $88.36 million | Q1 2016: -$33.87 million | Q2 2016: -$37.02 million | Q3 2016: -$34.93 million | Q4 2016: -$31.33 million | Q1 2017: -$39.51 million | Q2 2017: -$33.49 million | Q3 2017: -$28.61 million | Q4 2017: -$29.02 million | Q1 2018: -$37.71 million | Q2 2018: -$30.27 million | Q3 2018: -$22.93 million | Q4 2018: -$12.37 million | Q1 2019: -$17.47 million | Q2 2019: -$18.55 million | Q3 2019: $224.68 million | Q4 2019: -$47.22 million | Q1 2020: -$62.44 million | Q2 2020: -$64.58 million | Q3 2020: $86.68 million | Q1 2021: -$20.84 million | Q2 2021: -$17.96 million | Q3 2021: -$22.96 million | Q1 2022: -$23.38 million | Q2 2022: -$24.01 million | Q3 2022: -$23.10 million | Q1 2023: -$31.14 million | Q2 2023: -$44.24 million | Q3 2023: -$49.63 million | Q1 2024: -$45.33 million | Q2 2024: -$55.35 million | Q3 2024: -$63.69 million | Q1 2025: -$25.68 million | Q2 2025: $3.74 million | Q3 2025: -$12.19 million.
- Over the full 17 years of available data (2009 to 2025), LEXICON PHARMACEUTICALS, INC.'s Operating Income Loss has grown by 45.6%.
- Historical annual values: Fiscal year 2025: -$48.91 million | Fiscal year 2024: -$197.12 million | Fiscal year 2023: -$171.75 million | Fiscal year 2022: -$100.76 million | Fiscal year 2021: -$87.09 million | Fiscal year 2020: -$47.80 million | Fiscal year 2019: $141.45 million | Fiscal year 2018: -$103.28 million | Fiscal year 2017: -$130.62 million | Fiscal year 2016: -$127.17 million | Fiscal year 2015: $1.47 million | Fiscal year 2014: -$100.37 million | Fiscal year 2013: -$102.37 million | Fiscal year 2012: -$108.42 million | Fiscal year 2011: -$114.10 million | Fiscal year 2010: -$95.72 million | Fiscal year 2009: -$89.96 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: